AIMS: The US National Cancer Institute recently developed the PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events). PRO-CTCAE is a library of questions for clinical trial participants to self-report symptomatic adverse events (e.g. nausea). The objective of this study is to inform evidence-based selection of a recall period when PRO-CTCAE is included in a trial. We evaluated differences between 1-, 2-, 3-, and 4-week recall periods, using daily reporting as the reference. METHODS: English-speaking patients with cancer receiving chemotherapy and/or radiotherapy were enrolled at four US cancer centers and affiliated community clinics. Participants completed 27 PRO-CTCAE items electronically daily for 28 days, and then weekly over 4 weeks, using 1-, 2-, 3-, and 4-week recall periods. For each recall period, mean differences, effect sizes, and intraclass correlation coefficients were calculated to evaluate agreement between the maximum of daily ratings and the corresponding ratings obtained using longer recall periods (e.g. maximum of daily scores over 7 days vs 1-week recall). Analyses were repeated using the average of daily scores within each recall period rather than the maximum of daily scores. RESULTS: A total of 127 subjects completed questionnaires (57% male; median age: 57). The median of the 27 mean differences in scores on the PRO-CTCAE 5-point response scale comparing the maximum daily versus the longer recall period (and corresponding effect size) was -0.20 (-0.20) for 1-week recall, -0.36 (-0.31) for 2-week recall, -0.45 (-0.39) for 3-week recall, and -0.47 (-0.40) for 4-week recall. The median intraclass correlation across 27 items between the maximum of daily ratings and the corresponding longer recall ratings for 1-week recall was 0.70 (range: 0.54-0.82), for 2-week recall was 0.74 (range: 0.58-0.83), for 3-week recall was 0.72 (range: 0.61-0.84), and for 4-week recall was 0.72 (range: 0.64-0.86). Similar results were observed for all analyses using the average of daily scores rather than the maximum of daily scores. CONCLUSION: A 1-week recall corresponds best to daily reporting. Although intraclass correlations remain stable over time, there are small but progressively larger differences between daily and longer recall periods at 2, 3, and 4 weeks, respectively. The preferred recall period for the PRO-CTCAE is the past 7 days, although investigators may opt for recall periods of 2, 3, or 4 weeks with an understanding that there may be some information loss.
AIMS: The US National Cancer Institute recently developed the PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events). PRO-CTCAE is a library of questions for clinical trial participants to self-report symptomatic adverse events (e.g. nausea). The objective of this study is to inform evidence-based selection of a recall period when PRO-CTCAE is included in a trial. We evaluated differences between 1-, 2-, 3-, and 4-week recall periods, using daily reporting as the reference. METHODS: English-speaking patients with cancer receiving chemotherapy and/or radiotherapy were enrolled at four US cancer centers and affiliated community clinics. Participants completed 27 PRO-CTCAE items electronically daily for 28 days, and then weekly over 4 weeks, using 1-, 2-, 3-, and 4-week recall periods. For each recall period, mean differences, effect sizes, and intraclass correlation coefficients were calculated to evaluate agreement between the maximum of daily ratings and the corresponding ratings obtained using longer recall periods (e.g. maximum of daily scores over 7 days vs 1-week recall). Analyses were repeated using the average of daily scores within each recall period rather than the maximum of daily scores. RESULTS: A total of 127 subjects completed questionnaires (57% male; median age: 57). The median of the 27 mean differences in scores on the PRO-CTCAE 5-point response scale comparing the maximum daily versus the longer recall period (and corresponding effect size) was -0.20 (-0.20) for 1-week recall, -0.36 (-0.31) for 2-week recall, -0.45 (-0.39) for 3-week recall, and -0.47 (-0.40) for 4-week recall. The median intraclass correlation across 27 items between the maximum of daily ratings and the corresponding longer recall ratings for 1-week recall was 0.70 (range: 0.54-0.82), for 2-week recall was 0.74 (range: 0.58-0.83), for 3-week recall was 0.72 (range: 0.61-0.84), and for 4-week recall was 0.72 (range: 0.64-0.86). Similar results were observed for all analyses using the average of daily scores rather than the maximum of daily scores. CONCLUSION: A 1-week recall corresponds best to daily reporting. Although intraclass correlations remain stable over time, there are small but progressively larger differences between daily and longer recall periods at 2, 3, and 4 weeks, respectively. The preferred recall period for the PRO-CTCAE is the past 7 days, although investigators may opt for recall periods of 2, 3, or 4 weeks with an understanding that there may be some information loss.
Authors: William A Wood; Allison M Deal; Antonia V Bennett; Sandra A Mitchell; Amy P Abernethy; Ethan Basch; Charlotte Bailey; Bryce B Reeve Journal: J Pain Symptom Manage Date: 2014-08-13 Impact factor: 3.612
Authors: Antonia V Bennett; Donald L Patrick; James F Lymp; Todd C Edwards; Christopher H Goss Journal: J Cyst Fibros Date: 2010-12 Impact factor: 5.482
Authors: Joan E Broderick; Joseph E Schwartz; Gregory Vikingstad; Michelle Pribbernow; Steven Grossman; Arthur A Stone Journal: Pain Date: 2008-05-01 Impact factor: 6.961
Authors: Jennifer L Hay; Thomas M Atkinson; Bryce B Reeve; Sandra A Mitchell; Tito R Mendoza; Gordon Willis; Lori M Minasian; Steven B Clauser; Andrea Denicoff; Ann O'Mara; Alice Chen; Antonia V Bennett; Diane B Paul; Joshua Gagne; Lauren Rogak; Laura Sit; Vish Viswanath; Deborah Schrag; Ethan Basch Journal: Qual Life Res Date: 2013-07-20 Impact factor: 4.147
Authors: Bryce B Reeve; Sandra A Mitchell; Amylou C Dueck; Ethan Basch; David Cella; Carolyn Miller Reilly; Lori M Minasian; Andrea M Denicoff; Ann M O'Mara; Michael J Fisch; Cynthia Chauhan; Neil K Aaronson; Corneel Coens; Deborah Watkins Bruner Journal: J Natl Cancer Inst Date: 2014-07-08 Impact factor: 13.506
Authors: Antonia V Bennett; Amylou C Dueck; Sandra A Mitchell; Tito R Mendoza; Bryce B Reeve; Thomas M Atkinson; Kathleen M Castro; Andrea Denicoff; Lauren J Rogak; Jay K Harness; James D Bearden; Donna Bryant; Robert D Siegel; Deborah Schrag; Ethan Basch Journal: Health Qual Life Outcomes Date: 2016-02-19 Impact factor: 3.186
Authors: S Carnio; D Galetta; V Scotti; D L Cortinovis; A Antonuzzo; S Pisconti; A Rossi; O Martelli; F L Cecere; A Lunghi; A Del Conte; E S Montagna; J Topulli; D Pelizzoni; S G Rapetti; M Gianetta; M V Pacchiana; V Pegoraro; N Cataldo; E Bria; S Novello Journal: Support Care Cancer Date: 2017-12-21 Impact factor: 3.603
Authors: Clara Scher; Emily Petti; Lauren Meador; Janet H Van Cleave; Eva Liang; M Carrington Reid Journal: Pain Manag Nurs Date: 2020-05-21 Impact factor: 1.929
Authors: Kirsten A Nyrop; Allison M Deal; Shlomit S Shachar; Ethan Basch; Bryce B Reeve; Seul Ki Choi; Jordan T Lee; William A Wood; Carey K Anders; Lisa A Carey; Elizabeth C Dees; Trevor A Jolly; Katherine E Reeder-Hayes; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Hyman B Muss Journal: Oncologist Date: 2018-12-14
Authors: Ethan Basch; Angela M Stover; Deborah Schrag; Arlene Chung; Jennifer Jansen; Sydney Henson; Philip Carr; Brenda Ginos; Allison Deal; Patricia A Spears; Mattias Jonsson; Antonia V Bennett; Gita Mody; Gita Thanarajasingam; Lauren J Rogak; Bryce B Reeve; Claire Snyder; Lisa A Kottschade; Marjory Charlot; Anna Weiss; Deborah Bruner; Amylou C Dueck Journal: JCO Clin Cancer Inform Date: 2020-10
Authors: Janet H Van Cleave; Mei R Fu; Antonia V Bennett; Mark S Persky; Zujun Li; Adam Jacobson; Kenneth S Hu; Allison Most; Catherine Concert; Maria Kamberi; Jacqueline Mojica; Amanda Peyser; Ann Riccobene; Anh Tran; Michael J Persky; Justin Savitski; Eva Liang; Brian L Egleston Journal: Mhealth Date: 2019-07-29
Authors: Henry A Glick; Taiga Miyazaki; Katsuji Hirano; Elisa Gonzalez; Luis Jodar; Bradford D Gessner; Raul E Isturiz; Adriano Arguedas; Shigeru Kohno; Jose A Suaya Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079
Authors: Mark A Samaan; Polychronis Pavlidis; Sophie Papa; Nick Powell; Peter M Irving Journal: Nat Rev Gastroenterol Hepatol Date: 2018-03-07 Impact factor: 46.802